Pathophysiology of Lichen Planus and Oral Lichen Planus
Both cutaneous and oral lichen planus are T-cell mediated autoimmune inflammatory disorders characterized by CD8+ cytotoxic T lymphocyte-driven destruction of basal keratinocytes, resulting in interface dermatitis and apoptosis of epithelial cells.
Core Immunopathogenic Mechanisms
Antigen-Specific Pathway
The pathogenesis involves a two-pronged immune attack combining antigen-specific and non-specific mechanisms 1, 2. The antigen-specific component centers on:
- Antigen presentation by basal keratinocytes acting as non-professional antigen-presenting cells
- CD8+ cytotoxic T-cell activation that specifically targets and kills keratinocytes expressing the inciting antigen
- Skewing of the T-cell receptor (TCR) repertoire toward oligoclonal expansion, suggesting a focused immune response against specific epitopes 3
Non-Specific Inflammatory Cascade
The non-specific mechanisms amplify tissue damage through:
- Mast cell degranulation in the superficial lamina propria, releasing inflammatory mediators
- Matrix metalloproteinase (MMP) activation, particularly MMP-9, which degrades the basement membrane zone
- Basement membrane disruption allowing intraepithelial T-cell migration and direct keratinocyte contact 1, 2
Cytokine-Mediated Inflammation
Recent research has identified critical cytokine pathways, particularly IL-17 and IL-22 as key drivers of oral lichen planus 4, 5. IL-22 serum levels are significantly elevated in oral lichen planus patients compared to controls (p<0.001), suggesting a pathogenic role specific to oral mucosal involvement 5. The IL-17/IL-23 axis promotes chronic inflammation and epithelial proliferation, creating a self-perpetuating inflammatory cycle 3.
Molecular Signaling Pathways
Epidermal growth factor receptor (EGFR) signaling serves as a molecular bridge between chronic inflammation and abnormal epithelial proliferation 3. This pathway may explain both the chronicity of disease and the potential for malignant transformation, as dysregulated EGFR signaling can promote cellular proliferation in the setting of ongoing DNA damage.
Disease Chronicity and Immune Privilege
OLP chronicity results from deficient TGF-β1-mediated immunosuppression 1. The normal oral mucosa functions as an immune-privileged site (similar to the eye, testis, and placenta), and breakdown of this immune privilege triggers autoimmune oral mucosal diseases 1. The inability to restore immune homeostasis perpetuates the inflammatory response.
Histopathologic Correlate
The unifying histopathologic feature across all clinical presentations is lichenoid interface dermatitis characterized by:
- Band-like lymphocytic infiltrate in the superficial lamina propria
- Liquefaction degeneration of the basal cell layer
- Civatte bodies (apoptotic keratinocytes)
- Saw-tooth rete ridge pattern (in cutaneous LP)
- Variable hyperkeratosis or epithelial atrophy depending on clinical subtype 4, 6
Differential Pathogenesis: Cutaneous vs. Oral
While sharing core T-cell mediated mechanisms, oral LP demonstrates distinct immunologic features including higher IL-22 levels and greater chronicity compared to cutaneous disease 5. Oral lesions tend to be more persistent and treatment-resistant, possibly due to constant antigenic stimulation from the oral microenvironment, including Candida colonization and altered oral microbiome 3.
Etiologic Triggers and Associations
HCV-Associated LP
In hepatitis C virus (HCV)-positive patients, LP results from T-cell mediated autoimmune reaction triggered by viral antigens 7. Type-1 interferons are major drivers of lichenoid inflammation, explaining why interferon-based antiviral therapy can induce or exacerbate LP 7.
Drug-Induced and ICI-Related LP
Immune checkpoint inhibitor (ICI)-related lichen planus occurs in up to 6% of patients receiving PD-1/PD-L1 inhibitors, with mean onset 6-12 weeks after treatment initiation 8. This represents immune dysregulation from checkpoint blockade, allowing unchecked T-cell activation against self-antigens.
Malignant Transformation Potential
The malignant transformation rate is approximately 1.43%, increasing to 5.13% in the presence of dysplasia 9. Carcinogenesis may be regulated by the balance between tumor inhibitors (TGF-β1, TNF-α, IFN-γ, IL-12) and promoters (MIF, MMP-9) within the chronically inflamed microenvironment 1. This underscores the importance of long-term surveillance.